Delhi HC Refuses Stay on HPV Immunisation, Seeks Centre's Response
UPSC / SSC current affairs note · Polity
Why in news
The Delhi High Court refused to stay the HPV immunisation campaign but directed the Centre, CDSCO, and ICMR to explain the vaccine's introduction within four weeks. The court was hearing a PIL raising concerns about long-term safety, informed consent, and adverse event monitoring. The next hearing is on October 29.
Background
HPV (human papillomavirus) vaccine is being considered for inclusion in India's Universal Immunisation Programme to prevent cervical cancer. A Public Interest Litigation challenged the decision, citing lack of safety data and proper protocols.
Key facts
Delhi High Court refused to stay the HPV immunisation campaign.
Court asked Centre, CDSCO, and ICMR to file replies in four weeks on justification for introducing the vaccine.
PIL sought review of HPV vaccine inclusion in Universal Immunisation Programme.
Concerns raised: long-term safety, lack of informed consent, monitoring of adverse events.
Court stated: 'Half-baked vaccines should not be administered. We are only to ensure that the necessary protocol is followed.'
PIL also sought district-wise and state-wise evaluations before further expansion.
Next hearing scheduled for October 29.
Prelims pointers
- HPV: Human Papillomavirus, causes cervical cancer.
- Universal Immunisation Programme (UIP): India's vaccination programme.
- CDSCO: Central Drugs Standard Control Organisation.
- ICMR: Indian Council of Medical Research.
- PIL: Public Interest Litigation.
- Delhi High Court.
Mains angles
- GS2 Polity: Role of judiciary in public health policy and PILs.
- GS2 Health: Vaccination programmes, informed consent, and regulatory oversight.
- GS3 Science & Technology: Vaccine development, safety protocols, and adverse event monitoring.